Nuclear factor erythroid 2(NRF2) can activate metabolic reconnection and increase the pathway involved in glutamine metabolism, which inhibits the chemotherapy resistance of KRAS mutant pancreatic cancer (112). The gene discussed is KRAS; the disease is pancreatic neoplasm.